Scarica l'app Stockscreener
4.23
3.68%
0.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMEA Giù?
Forum
Previsione
Biomea Fusion Inc Borsa (BMEA) Ultime notizie
Biomea Fusion Advances Diabetes Treatment with Positive Study Results - TipRanks
Biomea Fusion's SWOT analysis: clinical hold casts shadow on diabetes drug stock - Investing.com
Biomea Fusion shares hold with Buy rating after trial success By Investing.com - Investing.com Australia
Biomea Fusion shares hold with Buy rating after trial success - Investing.com
Biomea Fusion's (BMEA) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes - The Manila Times
Biomea Fusion Announces Positive Topline Results from - GlobeNewswire
Biomea Fusion's Diabetes Drug Shows Breakthrough Results in Phase II Trial, Achieves Key HbA1c Reductions - StockTitan
The Manufacturers Life Insurance Company Takes Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Analysts Set Biomea Fusion, Inc. (NASDAQ:BMEA) Target Price at $39.36 - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Rating of “Buy” by Analysts - Defense World
Biomea Fusion (NASDAQ:BMEA) Receives Buy Rating from HC Wainwright - Defense World
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) - The Manila Times
Biomea Fusion to Host Conference Call to Announce Topline - GlobeNewswire
Biomea Fusion to Unveil Key Phase II Diabetes Trial Results: COVALENT-111 Data Release Set for December - StockTitan
Biomea Fusion (NASDAQ:BMEA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Biomea Fusion's SWOT analysis: stock faces challenges amid clinical hold By Investing.com - Investing.com South Africa
Biomea Fusion, Inc. (NASDAQ:BMEA) Short Interest Update - MarketBeat
Biomea Fusion's SWOT analysis: stock faces challenges amid clinical hold - Investing.com
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - The Manila Times
Biomea Fusion Announces Oral and Poster Presentations of - GlobeNewswire
Biomea Fusion Unveils Breakthrough Preclinical Data: Menin Inhibitor Boosts GLP-1 Therapy Effectiveness - StockTitan
Biomea Fusion (NASDAQ:BMEA) Earns “Buy” Rating from D. Boral Capital - Defense World
HC Wainwright Reaffirms “Buy” Rating for Biomea Fusion (NASDAQ:BMEA) - Defense World
HC Wainwright Reaffirms "Buy" Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia - The Manila Times
Biomea Fusion Announces Preliminary Data from Ongoing - GlobeNewswire
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 - EIN News
Fmr LLC Increases Stock Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia - GlobeNewswire
Biomea Fusion to Reveal Groundbreaking FLT3 Inhibitor Data for Acute Leukemia Treatment - StockTitan
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biomea Fusion Grants 30,000 Stock Options to New Employee Under Inducement Plan | BMEA Stock News - StockTitan
(BMEA) Investment Report - Stock Traders Daily
Biomea Fusion's SWOT analysis: clinical hold impacts diabetes drug stock - Investing.com India
Biomea Fusion's SWOT analysis: clinical hold impacts diabetes drug stock By Investing.com - Investing.com Canada
HC Wainwright Reaffirms Buy Rating for Biomea Fusion (NASDAQ:BMEA) - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024) - The Manila Times
Late-Breaker Oral Presentation Showing New Analysis from - GlobeNewswire
Biomea Fusion's Diabetes Drug Shows 1.23% HbA1c Drop in Key Patient Group | BMEA Stock News - StockTitan
We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate - Yahoo Finance
Airbnb CEO’s Counterintuitive Leadership Playbook for the $85 Billion Brand - Yahoo Finance
How To Trade (BMEA) - Stock Traders Daily
Biomea Fusion, Inc. Reveals Preclinical Data on Icovamenib and BMF-650 in Recent SEC Filing - Defense World
Biomea Fusion's SWOT analysis: clinical hold clouds diabetes drug stock outlook - Investing.com India
Biomea Fusion FY2024 EPS Estimate Raised by HC Wainwright - Defense World
HC Wainwright Forecasts Increased Earnings for Biomea Fusion - MarketBeat
Biomea Fusion (NASDAQ:BMEA) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Biomea Fusion’s (BMEA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
BMEABiomea Fusion, Inc. Latest Stock News & Market Updates - StockTitan
Biomea Fusion stock PT raised by Piper Sandler, citing pipeline potential - Investing.com Australia
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):